TW202506187A - 葡聚糖與tlr7促效劑之複合體 - Google Patents

葡聚糖與tlr7促效劑之複合體 Download PDF

Info

Publication number
TW202506187A
TW202506187A TW113113616A TW113113616A TW202506187A TW 202506187 A TW202506187 A TW 202506187A TW 113113616 A TW113113616 A TW 113113616A TW 113113616 A TW113113616 A TW 113113616A TW 202506187 A TW202506187 A TW 202506187A
Authority
TW
Taiwan
Prior art keywords
formula
compound
group
bonded
cancer
Prior art date
Application number
TW113113616A
Other languages
English (en)
Chinese (zh)
Inventor
髙梨洋輔
坂仁志
上町昊
永井康裕
Original Assignee
日商住友製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商住友製藥股份有限公司 filed Critical 日商住友製藥股份有限公司
Publication of TW202506187A publication Critical patent/TW202506187A/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • C07D239/49Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW113113616A 2023-04-12 2024-04-11 葡聚糖與tlr7促效劑之複合體 TW202506187A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2023-065007 2023-04-12
JP2023065007 2023-04-12

Publications (1)

Publication Number Publication Date
TW202506187A true TW202506187A (zh) 2025-02-16

Family

ID=93059496

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113113616A TW202506187A (zh) 2023-04-12 2024-04-11 葡聚糖與tlr7促效劑之複合體

Country Status (4)

Country Link
JP (1) JPWO2024214771A1 (https=)
CN (1) CN121311513A (https=)
TW (1) TW202506187A (https=)
WO (1) WO2024214771A1 (https=)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011008A (en) * 1997-01-08 2000-01-04 Yissum Research Developement Company Of The Hebrew University Of Jerusalem Conjugates of biologically active substances
WO2017061532A1 (ja) * 2015-10-07 2017-04-13 大日本住友製薬株式会社 ピリミジン化合物
CN107304232B (zh) * 2017-05-20 2020-07-28 杭州师范大学 一种葡聚糖/吲哚美辛接枝物的合成方法与应用
US10722591B2 (en) * 2017-11-14 2020-07-28 Dynavax Technologies Corporation Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof

Also Published As

Publication number Publication date
CN121311513A (zh) 2026-01-09
JPWO2024214771A1 (https=) 2024-10-17
WO2024214771A1 (ja) 2024-10-17

Similar Documents

Publication Publication Date Title
JP6970859B2 (ja) TAMおよびMETキナーゼの阻害薬としてのピラゾロ[3,4−b]ピリジン化合物
JP7085985B2 (ja) 悪性腫瘍治療用製剤及び組成物
EP3373932B1 (en) Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
JP7719072B2 (ja) 三分岐n-アセチルガラクトサミン修飾ヒドロキシルポリアミドアミンデンドリマーおよびその使用方法
WO2022262516A1 (zh) 连接子及其缀合物
US20240033266A1 (en) Combination therapy involving diaryl macrocyclic compounds
US20240009321A1 (en) Immunogenic nanovesicles for cancer immunotherapy
WO2015117551A1 (zh) 吡咯取代吲哚酮类衍生物、其制备方法、包含该衍生物的组合物、及其用途
WO2024017229A1 (zh) 一种吡咯并三嗪类化合物在制备抗肿瘤药物中的应用
WO2022138944A1 (ja) Swi/snf複合体機能異常がんの合成致死性に基づく治療法
CN101302199B (zh) 桂德霉素及其在制备抗肿瘤药物中的应用
CN112010839A (zh) 靶向丝/苏氨酸激酶抑制剂的晶型
ES2458818T3 (es) Métodos para evaluar la actividad de una composición de polisacárido
TW202506187A (zh) 葡聚糖與tlr7促效劑之複合體
JP6461088B2 (ja) 高分子化カンプトテシン誘導体及び高分子化hsp90阻害剤誘導体を含む医薬組成物
WO2020105701A1 (ja) 新規ポリマー-活性薬物-コンジュゲート及びその用途
CN120676939A (zh) Pi3k抑制剂及其制备和使用方法
WO2020204173A1 (ja) 水溶性アジュバントおよびそれを含有する組成物
WO2015125640A1 (ja) カンプトテシン誘導体とhsp90阻害剤の結合した高分子化合物及びその用途
RU2697551C2 (ru) Новые производные peg
WO2023008462A1 (ja) 癌の治療及び/又は予防のための医薬品
CN119770678B (zh) 一种葡萄柚细胞外囊泡负载三功能四价铂化合物的纳米药物及其制备方法和应用
WO2025263617A1 (ja) コレステロールとtlr7アゴニストのコンジュゲート体およびそれを含む医薬組成物
EP3747909B1 (en) Anticancer agent
WO2026054677A1 (en) Trastuzumab-drug conjugate